Arcturus Therapeutics saw the highest growth of 0.82% in patent filings in April and 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.82% and grants by 0.13%. GlobalData’s DataBook provides a comprehensive analysis of Arcturus Therapeutics‘s patent filings and grants. Buy the databook here.
Arcturus Therapeutics has been focused on protecting inventions in European Patent Office(EPO) with seven publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 25% of filings. The European Patent Office(EPO), United States(US), Australia(AU), and Brazil(BR) patent Office are among the top ten patent offices where Arcturus Therapeutics is filings its patents. Among the top granted patent authorities, Arcturus Therapeutics has 50% of its grants in Spain(ES).
Arrowhead Pharmaceuticals could be the strongest competitor for Arcturus Therapeutics
Patents related to nanomedicine and climate change lead Arcturus Therapeutics's portfolio
Arcturus Therapeutics has the highest number of patents in nanomedicine followed by, climate change and rare diseases. For nanomedicine, nearly 47% of patents were filed and 100% of patents were granted in Q2 2024.
Breast cancer related patents lead Arcturus Therapeutics portfolio followed by uterine cancer, and bone cancer
Arcturus Therapeutics has highest number of patents in breast cancer followed by uterine cancer, bone cancer, brain cancer, and thyroid cancer.
For comprehensive analysis of Arcturus Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.